Baseline characteristics of patients
| All patients n=782 | |
|---|---|
| Women, n (%) | 599 (76.6) |
| Age (years), mean (SD) | 48.3 (12.5) |
| Income, n (%): | |
| <€1220 | 392 (51.8) |
| ≥€1220 | 365 (48.2) |
| Missing value | 25 (3.2) |
| Professional status, n (%): | |
| Full-time | 381 (48.7) |
| Part-time | 82 (10.5) |
| Retired | 152 (19.4) |
| Homemaker | 60 (7.7) |
| Other | 107 (13.7) |
| Body mass index (kg/cm2), mean (SD) | 25.0 (4.6) |
| Symptom duration (weeks), mean (SD) | 10.8 (11.0) |
| Morning stiffness (min), median (IQR) | 60.0 (15.0 to 120.0) |
| Pain (VAS), mean (SD) | 55.6 (25.7) |
| Number of tender joints*, median (IQR) | 6.0 (3.0 to 13.0) |
| Number of swollen joints*, median (IQR) | 6.0 (3.0 to 10.0) |
| Disease activity score*, mean (SD) | 5.1 (1.3) |
| State of health (VAS), median (IQR) | 60.0 (45.0 to75.0) |
| Health assessment questionnaire score, mean (SD) | 1.0 (0.7) |
| C-reactive protein level (mg/l), median (IQR) | 9.0 (0.0 to 24.0) |
| Rheumatoid factor or anti-cyclic citrullinated peptide antibodies positivity, n (%) | 434 (55.5) |
| Human leucocyte antigen DRB*01 or 04 positivity, n (%) | 407 (52.0) |
| Erosion score, median (IQR) | 1.0 (0.0 to 3.0) |
VAS, visual analogue scale.
↵* disease activity score on 28 joints: number of tender and swollen joints among 28 joints.